PGx Clinical Pathway Development Study: Version 2.0
Research type
Research Study
Full title
Pharmacogenetic (PGx) Clinical athway Development Study: Version 2.0
IRAS ID
273748
Contact name
Essra Youssef
Contact email
Sponsor organisation
University of East Anglia
Duration of Study in the UK
0 years, 2 months, 27 days
Research summary
Many of us are now aware that our genes can play a role in our appearance, susceptibility to disease and even our personality. Our genes can also play a role in how we react to medicines. One of the most widely studied ways in which we differ is in the genes that control how our liver processes medicines. The study and practice of identifying these genes is called pharmacogenetics (PGx). PGx testing is helpful for doctors and pharmacists to choose medicines that are best for each patient and in what amount so they are more likely to work and less likely to cause side effects.
PGx testing is available in the USA, Canada, Australia and other countries in the EU. Within the UK, we have limited access to this testing outside of private care, therefore information to support how best to fit this technology into our current healthcare systems is lacking. This presents a challenge to designing future studies that can measure the cost-effectiveness of PGx testing which is a necessity for adoption by the NHS.
30 patients from three different settings (2 General practices, 2 Hospitals and 1 Mental Health Trust) will be able to access PGx testing through an independent prescriber or pharmacist. We will develop potential ways in which PGx testing can be delivered at each site. We will then interview prescribers, pharmacists and patients to understand what some of the barriers and facilitators are for PGx testing from a UK perspective.
We will produce a publication with the results from what we have learned. The information from this study will be used to design a future study to answer our question about the feasibility of PGx testing.REC name
Social Care REC
REC reference
19/IEC08/0062
Date of REC Opinion
28 Feb 2020
REC opinion
Further Information Favourable Opinion